{
  "id": "77e95aad20164581",
  "title": "Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+ / HER2 -/ PIK3CA Wild - Type Advanced Breast Cancer",
  "description": "20260120T163000Z",
  "content": "",
  "source": "portal.sina.com.hk",
  "source_url": "https://portal.sina.com.hk/finance/finance-globenewswire/globenewswire/2026/01/20/1456534/celcuity-announces-fda-acceptance-of-new-drug-application-for-gedatolisib-in-hr-her2-pik3ca-wild-type-advanced-breast-cancer/",
  "published_at": "20260120T163000Z",
  "fetched_at": "2026-01-21T00:24:36.527019+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda",
    "drug"
  ],
  "location": "Hong Kong",
  "raw_data": {
    "url": "https://portal.sina.com.hk/finance/finance-globenewswire/globenewswire/2026/01/20/1456534/celcuity-announces-fda-acceptance-of-new-drug-application-for-gedatolisib-in-hr-her2-pik3ca-wild-type-advanced-breast-cancer/",
    "url_mobile": "",
    "title": "Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+ / HER2 -/ PIK3CA Wild - Type Advanced Breast Cancer",
    "seendate": "20260120T163000Z",
    "socialimage": "https://ml.globenewswire.com/media/NGY1ZjFhYzgtYjY3My00ZDc1LWJjYTktNmI5MjdiM2VkZGRkLTExNjg1NzMtMjAyNi0wMS0yMC1lbg==/tiny/Celcuity-Inc-.png",
    "domain": "portal.sina.com.hk",
    "language": "English",
    "sourcecountry": "Hong Kong"
  }
}